its action as an antitumour agent is thought to be due to this inhibition.
Little information is available on the effect of MTX in the whole animal, although its distribution and metabolism have been investigated (Henderson et al., 1965a,b) and much work has been carried out on isolated cells or in vitro (Goldman, 1977) . Barford et al. (1976) Animals were then housed in metabolism cages (Jencons Metabowls, Jencons (Scientific) Limited, Hemel Hempstead, Herts.) designed for the separate collection of urine and faeces. Twenty-four hours after being dosed with radioactivity animals were killed and the livers removed into ice-cold beakers. Throughout all experiments animals were allowed food and water ad libitum.
Measurement of total radioactivity in livers faeces and urine samples. Livers and faeces -were freeze-dried and then ground to give a homogeneous powder. 100mg samples were used to estimate total radioactivity as described in Barford et al. (1977) . Urine samples were counted as described in .
Preparationt of liver extracts.-Liver extracts were prepared as described in Barford et al. (1977) to prevenit breakdown of folate polyglutamates.
Column chromatoygraphy.-Liver extracts and urine samples were chromatographed on DEAE cellulose and Sephadex G.15 as described in .
Measurement of radioactivity in columnn effluents.-Radioactivity in column effluents was determined as described in (Table II) . 
Recovery of radioactivity in urine samples The recovery of radioactivity in urine samples over the 24h period is shown in Table III . Control animals excrete 8.5% of a dose of 2-[14C]-folic acid in urine in 6 h. When 2-[14C]-folic acid is given after MTX significantly more radioactivity is excreted in urine in the first 6 h after administration of the dose. The urinary excretion of radioactivity being 22.2% of the dose (P < 0O001) after a dose of MTX of 10 mg/kg body wt. Much of this increase in urinary radioactivity is due to excretion of unmetabolized folic acid (Table IV) (Connor et al., 1979) . Analysis of the urine figures showed that the excess of 3H over 14C in the fractions associated with reduced folate was increased in animals dosed with MTX (Table V) . (Table II) .
McGuire et al. (1979) have shown that tetrahydrofolate is a substrate for pteroylpolyglutamate synthetase while folic acid is not. The inability of the liver to convert large quantities of 2-[14C]-folic acid to tetrahydrofolate and thus to polyglutamate may explain the decreased retention of radioactivity in the liver when radiolabelled folic acid is given after a dose of MTX. McBurney & Whitmore (1974) have suggested that conversion to polyglutamates serves to trap the folate monoglutamates that are transported into cells. MTX also decreases the retention of radioactivity in the liver when given 24 h before a dose of 2-[14C]-5-methyltetrahydrofolate, which is a poor substrate for pteroylpolyglutamate synthetase (McCGuire et al., 1979) . 5-methyltetrahydrofolate must lose the methyl group in vivo before it can be converted to a polyglutamate (Lavoie et al., 1974) , but no reduction step is necessary. MTX could reduce the levels of liver polyglutamate after a dose of 2-[14C]-5-methyltetrahydrofolate at a step other than inhibiting the reduction of dihydrofolate reductase, probably by inhibiting liver folate transport, or by accelerating the catabolism of liver folate polyglutamates (Connor et al., 1979) or both. That folate catabolism can occur after MTX is shown by the scission products after administration of mixed 3H-and 14(1 labelled folic acid (Barford et al., 1977) . The results presented in this paper demonstrate an increase in scission after MTX administration, possibly by inhibiting reduction of dihydrofolate to tetrahydrofolate by dihydrofolate reductase, or by inhibition of dihydropteridine reductase, an enzyme which may maintain tetrahydrofolates in the fully reduced state (Pollock & Kaufman, 1978) . The results presented here demonstrate that MTX affects the uptake and retention of labelled oral folates in the whole animal, and reduces the size of the liver folate polyglutamate pool which has an essential primary coenzyme function in purine and pyrimidine biosynthesis (Rowe, 1978) and thus the therapeutic effect may not be due solely to inhibition of dihydrofolate reductase, but also to changes in distribution of folates in the animal. This paper describes for the first time a reduction in incorporation of folates in the whole animal into an essential coenzyme pool by the action of MTX, and demonstrates an increase in scission of the folate molecule after MTX administration.
